-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Image: The research team led by Professor Martin Roelsgaard Jakobsen (right) and Associate Professor Rasmus Bak (left) has now clarified the key conditions needed to grow a large number of rare immune cells in the laboratory
Image Credit: Simon Byrial Fischel
A new study from Aarhus University has made significant progress in stem cell research and provides an opportunity to treat patients with a new cell-based immunotherapy
For the first time in the world, researchers from the Department of Biomedicine have successfully developed a rare but important immune cell plasmacytoid dendritic cell (pdc) based on stem cells in accordance with GMP (Good Manufacturing Practice) regulations
pDCs play an important central role in the immune system because they can recognize and fight viral infections
For this reason, pDCs have become a popular commodity in the research community, especially in the field of cellular immunotherapy, and they have great potential in this regard
Professor Martin Roelsgaard Jakobsen and Associate Professor Rasmus Bak explained that this research has exciting prospects
"With the cooperation of our two research groups, we have developed a GMP culture method, by providing blood stem cells with proper nutrition and conditions, we can generate millions of pDCs
"We know that pDCs play a crucial role in how the body fights diseases, such as SARS-CoV-2, and different types of cancer.
Difficult to extract from the blood
There are less than 0.
"We have a series of research projects based on the effective methods we just published
"We also have research projects to study how to use new genetic technology tools, such as CRISPR/Cas, on immune cells
The initial goal is to extract pDCs from the patient's own stem cells, which the researchers will use for treatment
Conduct clinical trials in the foreseeable future
The progress of cell therapy is one of the great hopes for the treatment of severe and chronic diseases
In their laboratory, Martin Roelsgaard Jakobsen and Rasmus Bak use stem cells from completely anonymous healthy donors, and pDCs are created in accordance with GMP (Good Manufacturing Practice) regulations, which makes this method suitable for treatment
The research team also hopes that their research team will have a cell therapy product ready for clinical testing within a few years
"As we further understand the interaction between immune cells and diseased tissues, cell therapy will play a huge role in the future
.
Here, we propose a new cell therapy with huge and untapped potential
.
In principle There are no restrictions on which diseases we can use it on," said Professor Martin Roelsgaard Jakobsen
.
Research results-more information
Researchers at Aarhus University have discovered a way to generate plasmacytoid dendritic cells (pDCs) from hematopoietic stem cells
.With the help of optimized cell conditions, combined with the implementation of stem cell pre-expansion, researchers can generate an average of 465 million stem cell-derived pDCs from 100,000 blood stem cells
.This experiment was the first to successfully generate fully functional pDCs from blood stem cells, laying the foundation for the study of these pDCs for cellular immunotherapy
.
It is expected that immunotherapy with pDCs can initiate the patient's immune response, thereby helping to fight cancer or infection
.
Original title:
Ascorbic acid supports ex vivo generation of plasmacytoid dendritic cells from circulating hematopoietic stem cells
